Candel Therapeutics Inc (NASDAQ:CADL) will host a webcast and conference call on May 15 at 1pm ET to discuss extended phase 3 data for CAN-2409 in intermediate- to high-risk localized prostate cancer.
The update follows an AUA 2026 presentation and will include insights from leading specialists Neal Shore, Jonathan Tward and Daniel George.
An archived replay will be available on the company’s website for 90 days.